Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal). NICE technology appraisal guidance 899
National Institute for Health and Care Excellence (NICE)
Record ID 32018011940
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta899
Year Published:
2023
URL for published report:
https://www.nice.org.uk/guidance/ta899
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Suicide Prevention
- Antidepressive Agents
- Ketamine
- Depressive Disorder, Major
- Suicide
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.